araag2/HINT huggingface dataset:
Clinical trial NCT00150813 (phase 3, status: completed)
Conditions: epilepsy, tonic-clonic
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: levetiracetam
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with a confirmed diagnosis of epilepsy.

          -  Subjects having experienced in the past unprovoked partial seizures (IA, IB, IC with
             clear focal origin),or generalized tonic-clonic seizures (without clear focal origin),
             that are classifiable according to the International Classification of Epileptic
             Seizures

          -  Subjects having participated in the previous double-blind monotherapy trial (N01061
             [NCT00150735] or N01093 [NCT00150787]).

          -  Male/female subjects (>= 16 years).

        Exclusion Criteria:

        - Need for an additional Antiepileptic Drug (AED).
Clinical trial NCT00339183 (phase 3, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: panitumumab, folfiri
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Man or woman at least 18 years old

          -  Diagnosis of metastatic colorectal cancer (mCRC)

          -  One and only one chemotherapy regimen for mCRC consisting of first-line 5-FU -based
             chemotherapy

          -  Radiologically documented disease progression per modified Response Evaluation
             Criteria in Solid Tumors (RECIST) criteria during treatment or within 6 months of last
             dose of first-line chemotherapy

          -  At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST

          -  Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2

          -  Paraffin-embedded tumor tissue from the primary tumor or metastasis available for
             central analyses

          -  Adequate hematologic, renal, and hepatic functions

          -  Negative pregnancy test within 72 hours of enrollment

          -  Other protocol-specified criteria may apply

        Exclusion Criteria:

          -  History of or known presence of central nervous system (CNS) metastases

          -  History of another primary cancer within 5 years of randomization

          -  Prior irinotecan therapy

          -  Prior anti-epidermal growth factor receptor (EGFr) antibody therapy or treatment with
             small molecule EGFr inhibitors

          -  Any investigational agent or therapy within 30 days before randomization

          -  Known allergy or hypersensitivity to irinotecan, 5-FU or leucovorin

          -  History of interstitial lung disease or evidence of interstitial lung disease on
             baseline chest computed tomography (CT) scan

          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhea

          -  Known positive tests for human immunodefiency virus (HIV), hepatitis C viris (HCV),
             acute or chronic active hepatitis B virus (HBV)

          -  Major surgery within 28 days of randomization or minor surgical procedure within 14
             days of randomization

          -  Pregnant or breast-feeding

          -  Man or woman of child-bearing potential not consenting to use adequate contraceptive
             methods or abstinence during the course of the study and for 6 months after last study
             drug administration (women) or 1 month after last study drug administration (men)

          -  Other protocol-specified criteria may apply
Clinical trial NCT01058291 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: kw-6500, kw-6500 placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have given written informed consent

          -  Patients who have Parkinson's disease

          -  Patients who have been on a stable regimen of levodopa plus at least one other
             antiparkinsonian agent and who have OFF state

          -  Patients who meet stage 4 or 5 while in the OFF state and stage 0 to 3 while in the ON
             state on the Modified Hoehn and Yahr Scale

          -  Patients who have experienced a 30% or more improvement in Unified Parkinson's Disease
             Rating Scale (UPDRS) partⅢ score when tested for responsiveness to levodopa during the
             baseline period

          -  Patients who have at least one OFF state per day

          -  Patients who can understand the expression of OFF state, ON state, and dyskinesia

          -  Patients or their families have a desire for self-injection of KW-6500

        Exclusion Criteria:

          -  Patients with an illness of the cardiac, hematologic, hepatic, renal, pancreatic,
             metabolic, respiratory, gastrointestinal, endocrinologic, or neurologic system
             (excluding Parkinson's disease)

          -  Patients with orthostatic hypotension

          -  Patients with a history of intolerance to morphine or its derivatives, sulfur,
             sulfur-containing pharmaceutical products, or sulfite

          -  Patients with a history of malignant syndrome

          -  Patients with a diagnosis of cancer or evidence of continued disease

          -  Patients who do not test negative in the direct Coombs' test

          -  Pregnant or lactating women, women who are planning to have children, women who test
             positive in the pregnancy test, or women who cannot adhere to a reliable method of
             contraception

          -  Patients who have received MAO inhibitors except selegiline

          -  Patients with a history of mental disease (excluding psychiatric symptoms associated
             with Parkinson's disease)

          -  Patients with a Mini-Mental State Examination score of 23 or less

          -  Patients who are taking antipsychotics or central dopamine antagonists (excluding
             domperidone)

          -  Patients who are receiving methyldopa or 5-HT3 receptor antagonists

          -  Patients who are receiving reserpine or papaverine

          -  Patients who have had a neurosurgical operation for Parkinson's disease

          -  Patients who have had transcranial magnetic stimulation

          -  Patients with a history of drug or alcohol abuse or dependence
Clinical trial NCT00126256 (phase 3, status: completed)
Conditions: colorectal cancer, metastasis
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: 5-fluorouracil, leucovorin, irinotecan, oxaliplatin
SMILES: FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastatic colorectal adenocarcinoma

          -  Unresectable metastasis

          -  Bidimensionally measurable disease (World Health Organization [WHO] criteria)

          -  WHO performance status of 2 or less

          -  Adequate hematologic functions (neutrophil count, at least 1500 per cubic millimeter;
             and platelet count, at least 100,000 per cubic millimetre)

          -  Adequate renal function (serum creatinine, less than 125 micromol per liter)

          -  Adequate liver function (bilirubin, not more than 5 times the upper limit of normal)

          -  No previous chemotherapy other than previous adjuvant chemotherapy or concomitant
             chemoradiotherapy with 5-fluorouracil and leucovorin for the treatment of the primary
             tumor completed at least 6 months before inclusion

          -  Signed written inform consent

          -  Quality of life questionnaire (QLQ C-30) filled out

        Exclusion Criteria:

          -  Pregnant or breast - feeding women

          -  Impossibility of regular follow-up for psychological, social or geographical reason

          -  Severe cardiac, respiratory, renal or hepatic failure

          -  Active coronary heart disease

          -  Patients with a history of a psychological illness or condition such as to interfere
             with the patient's ability to understand the requirements of the study

          -  Central nervous system metastases

          -  Past history of second malignancies

          -  Another investigational drug

          -  Chronic inflammatory bowel disease

          -  Previous chemotherapy with irinotecan or oxaliplatin based regimens
Clinical trial NCT00148447 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: escitalopram
SMILES: CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic schizophrenia patients,

          -  Age <60,

          -  Medicated,

          -  Inpatients and outpatients,on stable doses of antipsychotic medications for at least
             one month before the study entry.

          -  Patients will be clinically stable and free of any additional axis I diagnosis or
             significant medical illnesses before enrollment into the study.

          -  A Positive and Negative Syndrome Scale (PANSS) score of 50 or above will be required
             for entry to the study.

        Exclusion Criteria:

          -  Comorbidity with mania or major depression,

          -  Pregnancy,

          -  Lactation,

          -  Impaired renal or hepatic function,

          -  History of sensitivity to cipramil or to other drugs from the selective serotonin
             reuptake inhibitor (SSRI) group.

          -  Additional exclusion criteria will consist of mental retardation, organic conditions
             (brain tumors, drug abuse) and severe exacerbation of the psychiatric condition (i.e.
             suicide attempt, severe psychotic exacerbation) as defined by hospitalization in
             high-security units, clinical impression and CGI scores of "condition much worsened".

          -  Patients will be excluded during the study if they will remove their informed consent.
Clinical trial NCT00722566 (phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: velcade administered by subcutaneous injection, velcade administered by intravenous infusion
SMILES: CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female subjects 18 years or older

          2. Diagnosis of multiple myeloma

          3. Measurable, secretory multiple myeloma defined as serum monoclonal IgG of ≥10 g/L,
             serum monoclonal IgA or IgE ≥5 g/L, or serum monoclonal IgD ≥0.5g/L; or urine
             M-protein of ≥200 mg/24 hr

          4. Relapse or progression of myeloma following prior systemic antineoplastic therapy.

        Exclusion Criteria:

          1. Previous treatment with VELCADE

          2. More than 3 previous lines of therapy (separate lines of therapy are defined as single
             or combination therapies that are either separated by disease progression or by a
             greater than 6 month treatment-free interval)

          3. Peripheral neuropathy or neuropathic pain of NCI CTCAE Grade ≥2

          4. Any of the following within 3 weeks prior to randomization:

             antineoplastic or experimental therapy, corticosteroid use above 10mg a day
             (prednisone or equivalent), or plasmapheresis

          5. Any of the following within 2 weeks prior to randomization:

             radiation therapy, major surgery (kyphoplasty is not considered major surgery)

          6. Prior malignancy other than multiple myeloma diagnosed or treated within the last 2
             years, with the exception of completely resected carcinoma in situ or basal/squamous
             carcinoma of the skin
Clinical trial NCT00297115 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: roflumilast, placebo
SMILES: FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  COPD patients having at least one exacerbation within last year

          -  FEV1/FVC ratio (post-bronchodilator) ≤ 70%

          -  FEV1 (post-bronchodilator) ≤ 50% of predicted

        Main Exclusion Criteria:

          -  COPD exacerbation not resolved at first baseline visit

          -  Diagnosis of asthma and/or other relevant lung disease
Clinical trial NCT00615433 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: lurasidone, olanzapine, placebo comparator, lurasidone 40 mg tablets
SMILES: [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, [Na+].[Cl-], [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provide written informed consent and aged between 18 and 75 years of age.

          -  Meets DSM-IV criteria for a primary diagnosis of schizophrenia.

          -  Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate
             and reliable contraception for duration of study.

          -  Able and agrees to remain off prior antipsychotic medication for the duration of
             study.

          -  Good physical health on the basis of medical history, physical examination, and
             laboratory screening.

          -  Willing and able to comply with the protocol, including the inpatient requirements and
             outpatient visits.

        Exclusion Criteria:

          -  Considered by the investigator to be at imminent risk of suicide or injury to self,
             others or property.

          -  Any chronic organic disease of the CNS (other than schizophrenia).

          -  Used investigational compound within 30 days.

          -  Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence
             within the last 6 months
Clinical trial NCT00536913 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol pmdi 40/2.25ug + spacer, budesonide/formoterol pmdi 40/2.25 ug
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  children 6-11 years, diagnosed asthma treated

          -  6 months, PEF

          -  50% of predicted normal value pre-bronchodilator

        Exclusion Criteria:

          -  current systemic glucocorticosteroids usage

          -  current respiratory infection

          -  any significant disease or disorder as judged by investigator
Clinical trial NCT01067105 (phase 3, status: completed)
Conditions: perennial allergic rhinitis
ICD codes: D69.0, L50.0, B44.81, J30.89, J30.9, L20.84, H10.45
Drugs: ciclesonide hfa 160 μg
SMILES: [H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has successfully completed all visits of Study 060-633.

          -  Subject has given written informed consent and assent, including privacy authorization
             as well as adherence to concomitant medication withholding periods, prior to
             participation.

          -  Subject is male or female 12 years and older.

          -  Subject must be in general good health (defined as the absence of any clinically
             relevant abnormalities as determined by the Investigator) based on screening physical
             examination, clinical laboratory tests, and medical history.

          -  Subject, if female 65 years of age or younger, must have a negative urine pregnancy
             test (performed at Visit 1). Females of childbearing potential must be instructed to
             and agree to avoid pregnancy during the study and must use an acceptable method of
             birth control:

               1. An oral contraceptive, an intrauterine device (IUD), implantable contraceptive,
                  transdermal or injectable contraceptive for at least 1 month prior to entering
                  the study with continued use throughout the study and for thirty days following
                  study participation.

               2. Barrier method of contraception, eg, condom and/or diaphragm with spermicide
                  while participating in the study.

               3. Abstinence.

        Exclusion Criteria:

          -  Female subject who is pregnant or lactating.

          -  History of physical findings of nasal pathology, including nasal polyps.

          -  Subject has any condition that, in the judgment of the investigator, would preclude
             the subject from completing the study.
Clinical trial NCT01227655 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: bia 9-1067, placebo, levodopa, carbidopa, benserazide
SMILES: CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O, NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Able to comprehend and willing to sign an informed consent form.

          2. Male and female subjects between 30 and 83 years old, inclusive.

          3. Diagnosed with idiopathic PD according to the UK Parkinson's Disease Society Brain
             Bank Clinical Diagnostic Criteria for at least 3 years.

          4. Disease severity Stages I-III (modified Hoehn &Yahr staging) at ON.

          5. Treated with L-DOPA/DDCI for at least 1 year with clear clinical improvement.

          6. Treated with 3 to 8 daily doses of L-DOPA/DDCI, which can include a slow-release
             formulation.

          7. On a stable regimen of L-DOPA/DDCI and other anti-PD drugs for at least 4 weeks before
             screening.

          8. Signs of "wearing-off" phenomenon (end-of-dose deterioration) for a minimum of 4 weeks
             before screening with average total daily OFF time while awake of at least 1.5 hours,
             excluding the early morning pre-first dose OFF, despite optimal anti-PD therapy (based
             on the investigator's judgment.

        Exclusion Criteria:

          1. Non-idiopathic PD (atypical parkinsonism, secondary [acquired or symptomatic]
             parkinsonism, Parkinson-plus syndrome).

          2. Dyskinesia disability score >3 in the Unified Parkinson's Disease Rating Scale UPDRS)
             Sub-section IV A, item 33.

          3. Severe and/or unpredictable OFF periods.

          4. Treatment with prohibited medication: entacapone, tolcapone, neuroleptics,
             venlafaxine, MAO inhibitors (except selegiline up to 10 mg/day in oral formulation or
             1.25 mg/day in buccal absorption formulation or rasagiline up to 1mg/day), or
             antiemetics with antidopaminergic action (except domperidone) within the month before
             screening.

          5. Treatment with apomorphine within the month before screening or likely to be needed at
             any time during the study.

          6. Dosage change of concomitant anti-PD medication within 4 weeks of screening.

          7. Previous or planned (during the entire study duration, including the OL period)deep
             brain stimulation.

          8. Previous stereotactic surgery (e.g. pallidotomy, thalamotomy) for PD or with planned
             stereotactic surgery during the study period.

          9. Any investigational medicinal product within the 3 months (or within 5 half-lives,
             whichever is longer) before screening.

         10. Any medical condition that might place the subject at increased risk or interfere with
             assessments.
Clinical trial NCT00002597 (phase 3, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: flutamide, zoladex, lupron
SMILES: CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
Eligibility criteria:

        Inclusion criteria:

          -  Histologically confirmed locally confined adenocarcinoma of the prostate with primary
             tumors confined to the prostate, clinical stage T1b,1c, 2a or 2b.

          -  Negative nodes evaluated by imaging methods (classified in the study as NX) or by
             surgical sampling (classified in the study as N0).

          -  Karnofsky performance status ≥ 70.

          -  PSA is mandatory, must be ≤ 20)

          -  No prior hormonal therapy, radiation or chemotherapy.

          -  Prior finasteride for prostate hypertrophy allowed if discontinued at least 60 days
             prior to randomization.

          -  Prior testosterone administration allowed if at least 90 days elapsed since last
             administration.

          -  No evidence of distant metastasis or other synchronous primary. Patients with prior
             invasive malignancy who were disease free for at least 5 years could be eligible with
             pre-randomization approval by the study chairman.

          -  Treatment begins within 21 days after randomization.

          -  Patients signs a study-specific informed consent form.

          -  Alanine Aminotransferase (ALT) within 2x upper normal limits.

        Exclusion criteria:

          -  Stage T1a or ≥ T2c disease.

          -  Lymph node involvement (N1 - N3).

          -  Evidence of distant metastasis. (M1)

          -  PSA > 20.

          -  Radical surgery or cryosurgery for carcinoma of the prostate, previous irradiation,
             antiandrogen therapy or chemotherapy.

          -  Previous or concurrent cancers other than basal cell or squamous cell skin carcinoma.

        Patients with squamous cell carcinomas required to be NED (no evidence of disease) for a
        minimum of two years prior to study entry.

          -  Major medical or psychiatric illness which, in the investigator's opinion, would
             prevent completion of treatment and would interfere with follow-up.

          -  Karnofsky performance status of < 70.